BUZZ-Definium rises on FDA's 'breakthrough' tag for depression drug

** Shares of Definium Therapeutics DFTX.O rise 2.2% to $38.92

** Co says its LSD-based experimental pill DT120 receives FDA breakthrough therapy designation to treat major depressive disorder, or MDD

** The breakthrough therapy tag is meant to speed up development and review of drugs to treat serious conditions or those with unmet medical needs

** The FDA grants the tag after late-stage trial data show DT120 significantly reduces depression symptoms versus placebo

** The tag "provides another vote of confidence that DFTX's trial designs are aligned with FDA expectations," say Stifel analysts

** DT120 now holds FDA breakthrough therapy tag for both MDD and generalized anxiety disorder

** As of last close, stock more than doubled YTD